Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile By Ogkologos - October 6, 2026 7 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PATHFINDER 2 study Source RELATED ARTICLESMORE FROM AUTHOR Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... MOST POPULAR Mutation Screening Could Reveal Whether Hormone Treatment Will Work for Breast... April 23, 2021 Qué debo saber sobre los programas de emparejamiento de ensayos clínicos... November 28, 2023 Front-line Anti-PD1 Treatment Outperforms BRAF/MEK Therapy in BRAFV600-mutant Advanced Melanoma December 9, 2020 Colorectal Cancer Screening: Where Does the Shield Liquid Biopsy Fit In? October 11, 2024 Load more HOT NEWS A tribute to Professor Anne Charlton FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA-mutated Metastatic... FDA Approves Pembrolizumab with Chemotherapy for Biliary Tract Cancer A new IARC live webinar on evidence in primary cancer prevention
